The Japanese Pharmaceutical Market 2008-2023

Last year, the Japanese pharmaceutical market was the second largest in the world, with a value of $58.5bn. However, Japan’s market has experienced growth at a much lower rate than the other major pharmaceutical markets. It is at a key stage in its development. You need to take notice of these changes.

For many years the market has been dominated by the pricing and reimbursement policy of the Japanese government, which is arguably the most stringent of all the major governments. A determination to maintain tight cost controls on healthcare in Japan has resulted in the cost of drugs being tightly controlled. The government imposes limits on the price of drugs, and these are reduced every two years. This situation has caused concern to the international pharma industry, which remains eager to make further inroads into that large market. Are you achieving the success you should in Japan?

It is this imposed price control that is the key determining factor in influencing the shape, size and potential of the Japanese pharmaceutical market. The Japanese pharmaceutical market should have greater growth. However, the expansion of that market is influenced by several factors, including:

• Biennial National Health Insurance drug price reductions
• Increasing R&D expenses
• Intensifying competition between domestic companies and foreign international pharmaceutical companies, especially market leaders
• Restructuring within the pharmaceutical industry in Japan and worldwide
• Non-availability of many leading international products
• Relatively low use of generics
• A regulatory system that has recently become more accessible to international pharma companies.

The Japanese pharmaceutical market is at the start of a cycle that will see an increasing number of mergers and overall consolidation. The extent of the mergers involving a global pharmaceutical company buying out a smaller Japanese company will depend largely on the pipeline of the Japanese company involved. Global pharmaceutical companies, such as Pfizer, are already establishing a major presence in Japan.

The Japanese Pharmaceutical Market 2008-2023 examines that leading market critically, through a comprehensive review of available information. Sources include in-depth interviews, primary research, industrial databases, commercial news, in-house reports and economic research. Visiongain also applied financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion. This information is not available anywhere else.

In particular, this Japanese pharmaceutical market report from visiongain concentrates on the following essential aspects of that market:

• Discussion of the current Japanese pharmaceutical market in the context of the global pharma market
• Forecast of the overall Japanese pharmaceutical market from 2008 to 2023
• Drivers and restraints facing the Japanese market
• Opportunities and threats facing the Japanese market
• Commercial prospects for the market-leading drugs, with sales forecasts from 2008 to 2023
• Individual forecasts of the leading drug classes from 2008 to 2023
• The potential of generics manufacturers to penetrate this market
• Relevant pipeline developments with blockbuster potential
• Currently marketed drugs with blockbuster potential
• Discussion of unmet therapeutic needs

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for the Japanese pharmaceutical market from 2008 to 2023
• To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2008 to 2023, both by major therapeutic area and leading products
• To determine prospects of leading companies in that market
• To discover "hot" pipeline developments and up-and-coming products
• To determine the forces that influence the Japanese market: drivers, restraints, strengths, weaknesses, opportunities and threats
• To find out where the market is heading - both technologically and commercially from 2008 onwards